D. Boral Capital reiterated their buy rating on shares of VolitionRx (NYSE:VNRX – Free Report) in a report released on Wednesday morning,Benzinga reports. D. Boral Capital currently has a $5.00 target price on the stock.
Several other research firms have also recently weighed in on VNRX. StockNews.com began coverage on VolitionRx in a report on Tuesday. They set a “sell” rating for the company. Benchmark reiterated a “hold” rating on shares of VolitionRx in a research report on Friday, November 22nd.
Check Out Our Latest Analysis on VolitionRx
VolitionRx Stock Up 3.5 %
Insiders Place Their Bets
In related news, CEO Cameron John Reynolds bought 139,811 shares of the company’s stock in a transaction that occurred on Monday, December 9th. The shares were purchased at an average cost of $0.57 per share, with a total value of $79,692.27. Following the completion of the acquisition, the chief executive officer now directly owns 2,117,404 shares in the company, valued at approximately $1,206,920.28. The trade was a 7.07 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Guy Archibald Innes purchased 174,764 shares of the stock in a transaction that occurred on Monday, December 9th. The shares were purchased at an average cost of $0.57 per share, for a total transaction of $99,615.48. Following the completion of the acquisition, the director now directly owns 617,085 shares of the company’s stock, valued at $351,738.45. This represents a 39.51 % increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders have bought 358,266 shares of company stock valued at $204,212. 12.80% of the stock is currently owned by insiders.
Institutional Trading of VolitionRx
An institutional investor recently raised its position in VolitionRx stock. Ground Swell Capital LLC grew its holdings in VolitionRx Limited (NYSE:VNRX – Free Report) by 78.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 45,959 shares of the company’s stock after purchasing an additional 20,249 shares during the quarter. Ground Swell Capital LLC’s holdings in VolitionRx were worth $28,000 at the end of the most recent quarter. Institutional investors own 8.09% of the company’s stock.
VolitionRx Company Profile
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.
See Also
- Five stocks we like better than VolitionRx
- 3 Warren Buffett Stocks to Buy Now
- Driving Forward: Lucid’s Growing Sales and Gravity SUV’s Impact
- The 3 Best Blue-Chip Stocks to Buy Now
- Why Amazon’s Next Earnings Could Trigger a Stock Breakout
- Stock Market Sectors: What Are They and How Many Are There?
- With This Kind of Data, The Fed Isn’t Cutting Rates This Year
Receive News & Ratings for VolitionRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRx and related companies with MarketBeat.com's FREE daily email newsletter.